DNA drug developer Seawolf launches with $100 million funding, Sanofi deal

By Reuters News

- Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi SASY.PA worth up to $1.2 billion, as it seeks to develop DNA-based medicines.

  • The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly LLY.N, CRISPR Therapeutics CRSP.BN and others

  • San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions

  • Seawolf could get milestone payments and royalties

  • CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much

  • Seawolf's technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses

  • The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack

  • The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis

  • Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028

  • But "we'll probably need to raise some additional capital" to reach that stage, Alcamo said

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk